Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.

Clinical and translational science - 1 Mar 2024

Huh Ki Young, Hwang Sejung, Na Joo Young, Yu Kyung-Sang, Jang In-Jin, Chung Jae-Yong, Yoon Seonghae

Abstract excerpt

Genetic variants affect drug responses, making pre-emptive genotyping crucial for averting serious adverse events (SAEs) and treatment failure. However, assessing the benefits of pre-emptive genotyping based on genetic distribution, drug exposure, and demographics is challenging. This study aimed to estimate the population-level benefits of pre-emptive genotyping in the Korean population using nationwide cohort...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Pharmacogenetics

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 38501281
DOI: 10.1111/cts.13772
PMCID: PMC10949179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.PMID 38501281Read ↗

Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients.Semantic proximity Read ↗

Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory MedicineSemantic proximity Read ↗

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?Semantic proximity Read ↗

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.Semantic proximity Read ↗

Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health SystemSemantic proximity Read ↗

Implementation of Pre-emptive Pharmacogenomics Testing in Outpatient Clinics in Asia (IMPT study)Semantic proximity Read ↗

Ethical, legal and social/societal implications (ELSI) of recall-by-genotype (RbG) and genotype-driven-research (GDR) approaches: a scoping review.Semantic proximity Read ↗

Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial.Semantic proximity Read ↗

Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical PracticeSemantic proximity Read ↗

Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.Semantic proximity Read ↗

Assessment of the Implementation of Pharmacogenomic Testing in a Pediatric Tertiary Care SettingSemantic proximity Read ↗

[A DNA medication pass for everyone?]Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.